Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 4,740,000 shares, a growth of 25.7% from the September 15th total of 3,770,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is currently 4.3 days. Approximately 9.1% of the shares of the stock are short sold.
Several research firms have weighed in on ZVRA. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Monday, September 30th. William Blair upgraded shares of Zevra Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a report on Friday. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Wednesday, September 18th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $20.83.
Check Out Our Latest Stock Analysis on ZVRA
Shares of NASDAQ ZVRA opened at $8.16 on Friday. The business has a 50-day moving average of $7.44 and a 200-day moving average of $5.87. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market capitalization of $429.38 million, a price-to-earnings ratio of -4.86 and a beta of 1.94.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. As a group, sell-side analysts predict that Zevra Therapeutics will post -1.63 earnings per share for the current fiscal year.
In other news, Director Thomas Anderson acquired 10,000 shares of the firm's stock in a transaction on Tuesday, July 16th. The shares were purchased at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the transaction, the director now owns 20,000 shares of the company's stock, valued at approximately $136,200. This represents a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of ZVRA. Price T Rowe Associates Inc. MD acquired a new stake in Zevra Therapeutics during the 1st quarter worth approximately $64,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after buying an additional 2,452 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Zevra Therapeutics in the third quarter valued at about $105,000. City State Bank grew its stake in shares of Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Zevra Therapeutics during the fourth quarter worth about $177,000. Institutional investors and hedge funds own 35.03% of the company's stock.
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.